Diamonds and Dogs

June 23, 2014

Diamond: Agile Therapeutics (AGRX)

Agile Therapeutics started off the week with a boom of more than 50% by 1 o'clock. The stock soared to a yearly high of $12.55 and volume reached 1.4 million, about 5 times higher than its average. Agile Therapeutics, a women's health specialty company, announced the issuance of a new patent for the company's Skinfusion delivery device used in the contraceptive patch Twirla. Twirla is currently in Phase III development and is an important factor in the company's growth. The stock had its IPO on May 23 2014 at approximately $5.50 and has since doubled. Analysts still see a bright future for the company, as price targets are set at $17 and $18. Not too many stocks receive this kind of appraisal so soon after an IPO.

Dog: ParkerVision, Inc. (PRKR)

The dog of the day is ParkerVision, Inc., a developer of radio frequency technologies and products used in semiconductor circuits for wireless communication products. The stock price fell 60% on the day after the company lost a court decision in a lawsuit regarding accusations that Qualcomm (QCOM) infringed patents related to the wireless frequency-conversion technology. ParkerVision originally won the patent decision, but the ruling was overturned. Now, the company seems to be sinking lower and lower because the court case is burning much of the cash originally used for R&D or operating expenses. The company solely relies on its cash, as they have not made any revenue in years. ParkerVision's future looks pretty dim.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.